Test - Ascendis Pharma

NEWS RELEASES

November 7, 2024

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

November 4, 2024

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

September 30, 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Phase 1

Phase 2

Phase 3

TransCon hGH

Pediatric growth hormone deficiency2

test

Phase 2

test

Adult growth hormone deficiency

Phase 2

TransCon PTH

Adult hypoparathyroidism

Phase 3

Phase 1

Phase 2

Phase 3

sss

Phase 2

sdsd

sss

Phase 3

sss

sds

You are about to access www.ascendispharma.com.
Click below if you wish to proceed.

GO CANCEL

Sie verlassen nun die Ascendis Pharma-Webseite und werden auf eine externe Webseite weitergeleitet. Ascendis Pharma übernimmt keine Verantwortung für den Inhalt auf der externen Webseite.

WEITER ABBRECHEN